Novartis reports seven previously unknown tumors in children treated with Zolgensma

2 SOURCES UNITED STATESNEW

NOT MEDICAL ADVICE

This brief summarizes public reporting and official announcements. Research findings may be preliminary. Talk to a qualified clinician before making health decisions.

BLUF

Novartis has acknowledged seven previously unknown instances of tumors in children treated with its spinal muscular atrophy gene therapy, Zolgensma, according to STAT. The reports do not establish that the treatment caused the tumors.

HOW THIS BRIEF WAS MADE 1 outlet: 1 specialist. Automated sourcing and summaries by the BLUF engine. Corrections

Why it matters

The cases may be relevant to patients, families and clinicians weighing information about the therapy, but the articles provide no evidence establishing a causal link or describing a change to the treatment’s status.

What happens next

The supplied reports do not describe any announced regulatory decision, change to the therapy’s use or further investigation steps.

Any further information from Novartis about the cases

Any regulatory or clinical guidance related to the reported cases